Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration

被引:37
作者
Hedegaard, Sofie S. [1 ]
Hvas, Anne-Mette [2 ]
Grove, Erik L. [1 ]
Refsgaard, Jens [1 ]
Rocca, Bianca [3 ]
Davi, Giovanni [3 ]
Kristensen, Steen D. [1 ]
机构
[1] Aarhus Univ Hosp Skejby, Dept Cardiol, DK-8200 Aarhus, Denmark
[2] Aarhus Univ Hosp Skejby, Ctr Haemophilia & Thrombosis, Dept Clin Biochem, DK-8200 Aarhus, Denmark
[3] Univ G dAnnunzio, Ctr Excellence Aging, Chieti, Italy
关键词
Aspirin; Drug resistance; 11-dehydro-thromboxane B-2; Patient compliance; Platelet aggregation; Thromboxane B-2; MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; HIGH-RISK; RESISTANCE; METAANALYSIS; PREVENTION; STROKE; VOLUNTEERS; ACTIVATION; THERAPY;
D O I
10.1016/j.thromres.2008.12.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Aspirin reduces cardiovascular events in patients with coronary artery disease (CAD), but studies report a highly variable response to aspirin, often referred to as 'aspirin low-responsiveness'. We investigated whether 75 mg of daily non-enteric coated aspirin would completely inhibit the platelet cyclooxygenase-1 activity to a comparable extent in healthy individuals and stable CAD patients. Methods: We assessed serum thromboxane B-2 (S-TxB(2)), urinary 11-dehydro-TxB(2) (U-TxM) and arachidonic acid-induced optical platelet aggregometry (OPA) in 44 CAD patients on aspirin and in 22 healthy individuals before and after aspirin. OPA was performed in duplicate for four consecutive days during aspirin treatment after one week of treatment. Compliance was optimized by face-to-face interviews and pill counting and confirmed by S-TxB(2) measurements. Results: Aspirin inhibited S-TxB(2) > 99% in healthy individuals (median 1.1 ng/mL, interquartile range (IQR) = 0.8; 1.9 after aspirin) and in patients, S-TxB(2) Was reduced to a similar level (0.9 ng/mL (0.7; 1.5)). Healthy individuals had a median U-TxM of 278.5 pg/mg creatinine (229.5; 380.0) before aspirin and 68.5 pg/mg creatinine (59.0; 99.7) on aspirin corresponding to an average 74% inhibition of the endogenous TxA(2) biosynthesis. In patients median U-TxM was 67.5 pg/mg creatinine (54.0; 85.5). Seven study participants (11%) were aspirin low-responders according to OPA, but none had S-TxB(2) in the highest quartile. Conclusions: Low-dose aspirin suppressed S-TxB(2) to comparable levels in CAD patients and healthy individuals. Despite an almost complete inhibition of S-TxB(2), some participants were low-responders according to OPA. Thorough compliance control and use of thromboxane-specific assays are important when measuring platelet response to aspirin. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:96 / 100
页数:5
相关论文
共 33 条
[1]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[2]   PAIRED ANALYSIS OF URINARY THROMBOXANE-B2 METABOLITES IN HUMANS [J].
CATELLA, F ;
FITZGERALD, GA .
THROMBOSIS RESEARCH, 1987, 47 (06) :647-656
[3]   Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. [J].
Catella-Lawson, F ;
Reilly, MP ;
Kapoor, SC ;
Cucchiara, AJ ;
DeMarco, S ;
Tournier, B ;
Vyas, SN ;
FitzGerald, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (25) :1809-1817
[4]   Screening for aspirin resistance in stable coronary artery patients by three different tests [J].
Chakroun, Tahar ;
Addad, Faouzi ;
Abderazek, Fatma ;
Ben-Farhat, Mohamed ;
Hamdi, Sonia ;
Gamra, Habib ;
Hassine, Mohsen ;
Ben-Hamda, Khaldoun ;
Samama, Meyer M. ;
Elalamy, Ismail .
THROMBOSIS RESEARCH, 2007, 121 (03) :413-418
[5]   RADIOIMMUNOASSAY OF 11-DEHYDROTHROMBOXANE-B2 IN HUMAN-PLASMA AND URINE [J].
CIABATTONI, G ;
MACLOUF, J ;
CATELLA, F ;
FITZGERALD, GA ;
PATRONO, C .
BIOCHIMICA ET BIOPHYSICA ACTA, 1987, 918 (03) :293-297
[6]   Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers [J].
Cox, Dermot ;
Maree, Andrew O. ;
Dooley, Michelle ;
Conroy, Ronan ;
Byrne, Michael F. ;
Fitzgerald, Desmond J. .
STROKE, 2006, 37 (08) :2153-2158
[7]   Mechanisms of disease:: Platelet activation and atherothrombosis [J].
Davi, Giovanni ;
Patrono, Carlo .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (24) :2482-2494
[8]   Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction [J].
Dorsch, Michael P. ;
Lee, Jin Sun ;
Lynch, Donald R. ;
Dunn, Steven P. ;
Rodgers, Jo E. ;
Schwartz, Todd ;
Colby, Emily ;
Montague, Debbie ;
Smyth, Susan S. .
ANNALS OF PHARMACOTHERAPY, 2007, 41 (05) :737-741
[9]   Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events [J].
Eikelboom, JW ;
Hirsh, J ;
Weitz, JI ;
Johnston, M ;
Yi, Q ;
Yusuf, S .
CIRCULATION, 2002, 105 (14) :1650-1655
[10]   Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population [J].
Faraday, Nauder ;
Becker, Diane M. ;
Yanek, Lisa R. ;
Herrera-Galeano, Jesus Enrique ;
Segal, Jodi B. ;
Moy, Taryn F. ;
Bray, Paul F. ;
Becker, Lewis C. .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (06) :774-779